Skip to search formSkip to main contentSkip to account menu

ramelteon

Known as: (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide, ramelteon [Chemical/Ingredient] 
A synthetic melatonin analogue with hypnotic and circadian rhythm-modulating activities. Ramelteon binds to and activates melatonin receptors 1 and 2… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (1)

Indenes
Ramelteon M-II:MCnt:Pt:Tiss:QnRamelteon:MCnc:Pt:Ser/Plas:Qnramelteon 8 MG Oral Tablet [Rozerem]

Narrower (2)

RozeremTAK-375

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update
Rapid eye movement sleep behavior disorder (RBD) is a sleep behavior disorder characterized by abnormal behaviors and loss of… 
Review
2018
Review
2018
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia… 
Review
2012
Review
2012
Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction
  • R. Hardeland
  • TheScientificWorldJournal
  • 2012
  • Corpus ID: 14347676
Melatonin is a highly pleiotropic signaling molecule, which is released as a hormone of the pineal gland predominantly during… 
Highly Cited
2011
Highly Cited
2011
Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.
STUDY OBJECTIVES To evaluate the next-morning residual effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on driving… 
Highly Cited
2009
Highly Cited
2009
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
STUDY OBJECTIVES Long-duration (> or = 6 months) polysomnographic studies of insomnia medications are lacking. This study… 
Review
2009
Review
2009
Hypnotic use for insomnia management in chronic obstructive pulmonary disease.
2009
2009
Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study.
OBJECTIVE To evaluate the long-term safety and subjective sleep effects of ramelteon in adults with chronic insomnia. METHOD… 
Highly Cited
2006
Highly Cited
2006
Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High‐Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia
Ramelteon is a selective MT1/MT2 receptor agonist, indicated for insomnia treatment. Safety, tolerance, pharmacokinetics, and… 
Highly Cited
2005
Highly Cited
2005
Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist
Highly Cited
2005
Highly Cited
2005
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
OBJECTIVE Evaluate the efficacy of ramelteon, an MT/1MT2-receptor agonist, for the treatment of transient insomnia in healthy… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)